MedPath

A PET (positron emission tomography) clinical research study using prostate specific membrane antigen (PSMA) targeted tracer, 89Zr-Df-IAB2M

Phase 1
Conditions
Prostate cancer / Urothelial carcinoma / Renal cell carcinoma / Testicular cancer
Registration Number
JPRN-UMIN000015356
Lead Sponsor
niversity of Tsukuba
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

(1) In a clinical trial, patients who need to receive the new treatment (2) Patinets with severe pulmonary, renal, gastrointestinal, hematological or psychonurological disease (3) Patients whose doctors determined as inadequate for the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety: Subjective and Objective symptom, Vital data, Clinical tests, Radiation exposure, Adverse events
Secondary Outcome Measures
NameTimeMethod
1) Pharmacokinetics 2) Detection of cancer focus 3) PET imaging condition 4) Imaging of tumor neovascular
© Copyright 2025. All Rights Reserved by MedPath